- Company
- All 15 pharmaceutical unions gathered together
- by An, Kyung-Jin Oct 5, 2021 05:56am
- A labor union composed of workers from 15 domestic pharmaceutical and bio companies has begun in earnest to integrate. According to the industry on the 29th, representatives of labor unions from 15 pharmaceutical and bio companies currently active in Korea gathered to form the National Pharmaceutical & Bio Labor Union (NPU) and began offic
- Company
- Liver cancer pioneer ‘Nexavar,' the star in its guidelines
- by Eo, Yun-Ho Oct 1, 2021 06:09am
- There are two reasons why new drug development is slow for a certain disease: its marketability is low or the development of the drug is difficult. When developed, new drugs developed in the latter situation attract more widespread attention. Liver cancer (hepatocellular carcinoma) is a typical example of this. And the only targete
- Company
- Only Taejoon’s succeeds in avoiding Simbrinza’s patent
- by Kim, Jin-Gu Oct 1, 2021 06:09am
- Taejoon Pharmaceutical succeeds in avoiding the patent for Novartis’s glaucoma treatment ‘Simbrinza eyedrops (brimonidine+ brinzolamide).’ Being the only company to successfully avoid Novartis’s patent, Taejoon Pharmaceutical will now be able to develop a generic version of Simbrinza Eye Drops in a relatively relaxed manner. Acco
- Company
- Pfizer’s 2nd JAK inhibitor ‘Cibinqo’ to soon enter Korea
- by Eo, Yun-Ho Sep 30, 2021 05:57am
- Pfizer is planning to introduce a new JAK inhibitor after ‘Xeljanz’ to Korea. However, the new drug will target the ‘atopic dermatitis’ treatment market. According to industry sources, Pfizer Korea has recently submitted an application requesting marketing authorization for its Cibinqo (abrocitinib). The approval is expected to be mad
- Company
- It does not affect sales of Rivaroxaban 2.5mg
- by Kim, Jin-Gu Sep 30, 2021 05:57am
- Hanmi dismissed the possibility of legal disputes over the patent registration of the original company ahead of the launch of Xarelto's generic. The company said that the scope of validity of patents registered late does not affect Hanmi's new drug to be released. In addition, Hanmi emphasizes that it did not take issue when it sent certi
- Company
- The cumulative sales of Biktarvy amounted to ￦60 billion
- by Sep 30, 2021 05:56am
- Gilead Science's Biktarvy dominated the AIDS tx market around the world, including Korea, two years after its launch. Biktarvy consists of Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate as Gilead's HIV treatment. Compared to conventional treatments, the effectiveness and safety are improved, the expression rate of resi
- Company
- SK C&C-GC Pharma, establish a big data platform for healthca
- by Chon, Seung-Hyun Sep 30, 2021 05:56am
- SK C&C announced on the 27th that it will carry out a project with GC Pharma Holdings to build a comprehensive healthcare big data analysis platform based on artificial functions (AI). During the project period, the two companies analyze and map various standard medical data based on the "cloud-type digital platform" and conduct AI convergence a
- Company
- Generic for Xarelto is about to be released.
- by Kim, Jin-Gu Sep 30, 2021 05:56am
- Bayer's new oral anticoagulant (NOAC) Xarelto (Rivaroxaban)' generic is imminent to be released. In particular, Hanmi, which received generic exclusivity, plans to release Xarelto 2.5mg exclusively, and Hanmi has a patent dispute with Bayer, drawing keen attention to the future response of the two companies. According to the pharmaceutical in
- Company
- ST Pharm’s new cash cow ‘oligonucleotide’
- by Kim, Jin-Gu Sep 28, 2021 05:54am
- The oligonucleotide API business has become a major business of ST Pharm. The company has signed many deals over the past three years and the expansion and expectations for contract extensions have also greatly contributed to improving the company’s performance. Experts expect the oligonucleotide API business to stay as a cash cow for ST
- Company
- First progress to SGLT2i combo reimb. made in 3 years
- by Eo, Yun-Ho Sep 27, 2021 05:52am
- Patients in Korea have come one step closer to receiving reimbursement extensions to SGLT-2 inhibitor combos. This is the first progress that has been made in three years. According to industry sources, the diabetes expert committee that was convened by the Health Insurance Review and Assessment Service earlier this month concluded in the
